Enterprise Value to EBITDA Ratio: Aadi Bio (WHWK)
This daily price chart for the EV/EBITDA metric for Aadi Bioscience Inc (WHWK) shows 0.00. Aadi Bioscience Inc leverages AI bioinformatics and robotics for tumor combat modeling to eliminate routine tasks. The company generates revenue through exclusive patents on rare therapies, which provides significant pricing power. The humanitarian status of the medical field ensures stability, protecting its US operations from external conflicts.
Metric breakdowns and analytics for aadibio.com (WHWK)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
WHWK - Final Profit|Projected Future Earnings Aadi Bioscience Inc|WHWK - Price to Earnings Ratio|Forward P/E Multiple Aadi Bioscience|WHWK - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization WHWK|WHWK - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Aadi Bioscience|WHWK - Net earnings per share for the last four quarters|Quarterly EPS earnings growth aadibio.com|WHWK - Net earnings per share growth this year|Earnings growth forecast for next year Aadi Bioscience Inc
Fundamental company analysis:Aadi Bio WHWK
The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit, allowing for an assessment of the asset payback period regardless of debt load and tax distortions. For Aadi Bioscience Inc (WHWK), where R&D capital expenditures and strict FDA regulations determine the cost of entry, the company's EV/EBITDA trend reflects the balance between market expectations for nab-sirolimus patents and actual business efficiency.
Competitor analysis for Aadi Bioscience Inc
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|EV/EBITDA Multiple ERAS|EV/EBITDA Multiple delcath.com (DCTH)|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|EV/EBITDA Multiple Aura Biosciences Inc AURA|Candel - EV/EBITDA Multiple|ARAY (Accuray, Inc.) - Enterprise Value to Operating Income Before Depreciation|SLS: EV/EBITDA Multiple|ACTU - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio CTOR|HURA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TARA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FATE (Fate Pharma)|EV/EBITDA Multiple TCRX (TScan Therapeutics, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Champions Oncology Inc (CSBR)|XBIT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA CEL-SCI Corporation|OS Therapies Inc (OSTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RADX - Total Company Value to Operating Income Before Depreciation Ratio|ARTV (Artiva Biotherapeutics Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Adlai Nortye Limited (ANL)|EV/EBITDA Multiple VERU|Total Company Value to Operating Income Before Depreciation Ratio Tempest Therapeutics Inc|EV/EBITDA Multiple XLO (Xilio Therapeutics)|Renovaro Biosciences (RENB) - Company Value to EBITDA|MURA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|KAPA (Kairos Pharma Ltd) - Enterprise Value to Operating Income Before Depreciation|OKUR: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CytoMed Therapeutics Limited|CRIS (Curis Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Apollomics Corp APLM|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|ADVB (advanbiomed.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex)|Total Company Value to Operating Income Before Depreciation Ratio Calidi Biotherapeutics Inc. (CLDI)|SBFM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XBIO (Xenetic Biosciences) - Enterprise Value to Operating Income Before Depreciation|SLRX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio purple-biotech.com|Enterprise Value to EBITDA Ratio AONC|Enterprise Value to EBITDA Ratio BeiGene Ltd. (BGNE)|EV/EBITDA Multiple CKPT|ELEV (Elevation Oncology Inc.) - Business Value to Operating Income Before Depreciation|iCAD - Enterprise Value to EBITDA Ratio|IKNA - Enterprise Value to EBITDA Ratio|NTBL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VIRX - EV/EBITDA Multiple|MOR: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio NAYA Biosciences Corp|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
